CardioQ-ODM used as gold stan

RNS Number : 7964A

Deltex Medical Group PLC

15 October 2009

 



Deltex Medical Group plc

CardioQ-ODM™ used as gold standard for monitoring haemodynamic change

15 October 2009 - Deltex Medical Group plc ("Deltex Medical" or "Company"), the global leader in oesophageal Doppler monitoring ("ODM"), today announces the results of a further study using its CardioQ-ODM technology as the gold standard for monitoring haemodynamic changes in critically ill patients.

At the annual meeting of the European Society of Intensive Care Medicine in Vienna, Austria, the results of a trial at University College London Hospital were presented comparing readings from Deltex Medical's CardioQ-ODM to those from a more recently introduced device utilising Pulse Pressure Waveform Analysis ("PPWA"). Reference: ESICM 2009 abstract 0037.

The study, on critically ill patients in intensive care, noted unacceptably large percentage errors in the PPWA device relative to ODM and poor correlation after haemodynamic change. It noted that most validation studies of PPWA approaches had been performed in select groups of surgical patients and that few of these had assessed PPWA's ability to track change.

The study concluded that: the PPWA device "showed poor agreement" with ODM as the reference technique. Althought there may be weaknesses in ODM, it "has been successfully used in nine peri-operative outcome studies". Newer PPWA software versions also required testing and "evaluation of CO ("Cardiac Output") monitoring devices should routinely incorporate the ability to track CO changes".

Ewan Phillips, Deltex Medical's chief executive, commented:

"ODM measures haemodynamics in a fundamentally different way to PPWA. This latest study confirms ODM's growing status as the gold standard technique for accurately detecting changes in circulating blood volume and allowing effective, safe, timely interventions that benefit the patient."

For further information, please contact:-

Deltex Medical Group plc            01243 774 837

Nigel Keen, Chairman                    [e-mail]

Ewan Phillips, Chief Executive        [e-mail]

Paul Mitchell, Finance Director       [e-mail]

Nominated Adviser & Broker

Arden Partners plc                      020 7398 1600

Chris Hardie                                  [e-mail]

Matthew Armitt                              [e-mail]

Kreab Gavin Anderson                020 7554 1400

Deborah Walter                             [e-mail]

Robert Speed                                [e-mail]

  Notes for Editors

Deltex Medical manufactures and markets the CardioQ-ODM™ monitor, which uses disposable ultra-sound probes inserted into the oesophagus to determine the amount of blood being pumped around the body - 'circulating blood volume'. Reduced circulating blood volume is known as hypovolaemia, which leads to insufficient oxygen being delivered to the organs. This causes medical complications including peripheral and major organ failure which can lead to death. Hypovolaemia, which is akin to severe dehydration, affects virtually every patient having surgery because of the combined effects of pre-operative starvation, the impact of the anaesthetic agents and trauma from the surgery itself. Using fluids and drugs, guided by the CardioQ-ODM, to optimise the amount of circulating blood significantly reduces post-operative complications allowing patients to make a faster, more complete recovery and return home earlier.

The CardioQ-ODM incorporates the Company's proprietary software and a small diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is used for transmitting and receiving an ultra-sound signal. By using this technology, the CardioQ-ODM provides clinicians with the ability to haemodynamically optimise critically ill patients and those undergoing routine moderate to major surgery through the controlled administration of fluid and drugs. Haemodynamic optimisation has been scientifically proven to improve the speed and quality of patient recovery and reduce hospital stay.

There are already over 1,750 CardioQ-ODMs currently in use in hospitals worldwide and distribution arrangements are in place in over 30 countries. In addition, there are currently more than 200 clinical publications on the use of the CardioQ-ODM which have repeatedly:-

• Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works
• Proved that the CardioQ-ODM works in a wide range of surgical procedures
• Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients.

The SupraQ™ is an entirely non-invasive device which uses an ultrasound probe held at the base of the patient's neck to track the flow of blood in the aorta; it presents the same data as the CardioQ-ODM in a similar format and is used for taking snapshots or monitoring over short periods.

 

END

 

 

RESUSONRKSRRAAA